In agreement, around 75% of BC patients are diagnosed as HER2-negative luminal subtypes (with positive expression of hormone receptors), suggesting that the ER signaling pathway driven by estrogen is a major oncogenic pathway of most BC 56. Here, ERBB2 is linked to breast cancer.